BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Far-right AfD invited back to Munich Security Conference in 2026 - 2The World's Dazzling Regular Miracles
- 3My Excursion to Monetary Autonomy: Awesome ways to save cash
- 4NASA satellite gazes into Medusa Pool | Space photo of the day for Dec. 24, 2025
- 5Figure out How to Alter Your Volvo XC40 for Further developed Solace
- Takeaways from AP’s report on potential impacts of Alaska’s proposed Ambler Access Road
- Germany and trade unions kick off tough public-sector wage talks
- Israel explores creation of int'l force with Greece, Cyprus to deter Turkey
- Geminid meteor shower, one of the year's most reliable, peaks this weekend
- Investigating the World's Chief Authentic Urban communities to Visit
- Violence 'never part' of break-in plan, court told
- One dead, six wounded in various crime-related shootings in Israel over the weekend
- An Ideal Getaway - Spots for Solo Travel
- The Golden Globes is happening Sunday: Who's nominated, who's hosting and how to watch
